Pfizer provided three different outlooks for full-year 2020. Why such complicated guidance? The company plans to spin off its Upjohn unit and merge it with Mylan. Because of this pending transaction, Pfizer gave full-year 2020 guidance for the full company as it stands now, for the "new" Pfizer that will remain after the deal is finalized, and for Upjohn by itself.